Literature DB >> 19463204

Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications.

A Brett Hauber1, Ateesha F Mohamed, F Reed Johnson, David Meddis, Samuel Wagner, Liza O'Dowd.   

Abstract

The Onset-of-Effect Questionnaire (OEQ) is a self-administered instrument used to assess patient perception of how quickly asthma maintenance medications begin to work. This study was designed to quantify the relative importance that patients using combination inhaled corticosteroid and long-acting beta(2)-agonist (ICS/LABA) maintenance medication place on the onset-of-effect outcomes. Patients aged >or=18 years with a self-reported diagnosis of asthma, currently using combination ICS/LABA maintenance medication, completed an Internet-based SC conjoint survey instrument that included 10 choice trade-off tasks. In four choice tasks, patients were asked to choose between two hypothetical medications. In six choice tasks, patients were asked to choose among two hypothetical medications and their current medication. Each choice alternative was defined by response levels of the five OEQ statements and out-of-pocket cost. We used random-parameters logit methods to estimate the relative importance of outcomes assessed by the OEQ. Five hundred nine patients completed the study. Satisfied was the most important OEQ outcome and physical sensations were the least important. When offered a choice, 80% (95% CI, 75-85%) of patients preferred a maintenance medication for which they are satisfied with how quickly they feel it begins to work and 62% (95% CI: 57-67%) of patients preferred a maintenance medication that they feel begins to work right away. Combination maintenance medications with rapid onset of effect, especially those that impact a patients' ability to feel the medication work right away and patient satisfaction with how quickly the medication works, may increase the use of and adherence to maintenance medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19463204     DOI: 10.2500/aap.2009.30.3205

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  7 in total

1.  Patient preferences and linear scoring rules for patient-reported outcomes.

Authors:  Ateesha F Mohamed; A Brett Hauber; F Reed Johnson; Cheryl D Coon
Journal:  Patient       Date:  2010-12-01       Impact factor: 3.883

2.  Incentives for Blood Donation: A Discrete Choice Experiment to Analyze Extrinsic Motivation.

Authors:  Andrew Sadler; Ling Shi; Susanne Bethge; Axel Mühlbacher
Journal:  Transfus Med Hemother       Date:  2018-01-10       Impact factor: 3.747

3.  Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.

Authors:  Anna Bodzenta-Lukaszyk; Andrzej Dymek; Kirsten McAulay; Heikki Mansikka
Journal:  BMC Pulm Med       Date:  2011-05-23       Impact factor: 3.317

4.  Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat.

Authors:  Kimberly H Davis; Jun Su; Juan Marcos González; Jeremiah J Trudeau; Lauren M Nelson; Brett Hauber; Kelly A Hollis
Journal:  Health Qual Life Outcomes       Date:  2017-10-16       Impact factor: 3.186

5.  Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes.

Authors:  Richard D O'Connor
Journal:  Patient Relat Outcome Meas       Date:  2011-01-28

6.  Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment.

Authors:  Teresa Espanol; Johan Prevot; Jose Drabwell; Seema Sondhi; Laurence Olding
Journal:  Patient Prefer Adherence       Date:  2014-05-02       Impact factor: 2.711

7.  A Systematic and Critical Review of Discrete Choice Experiments in Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Hannah Collacott; Dian Zhang; Sebastian Heidenreich; Tommi Tervonen
Journal:  Patient       Date:  2021-07-12       Impact factor: 3.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.